This company can encode your favorite song in DNA—for $100000 – MIT Technology Review
MIT Technology Review |
This company can encode your favorite song in DNA—for $100000
MIT Technology Review Leproust is cofounder and CEO of Twist Bioscience, a five-year-old startup that is, by some estimates, the world’s largest supplier of manufactured DNA strands, or synthetic genes. Custom-ordered genes are the raw material of synthetic biology and the … |
EurekAlert (press release) |
It’s all about the (stem cell) neighborhood
EurekAlert (press release) A team headed by Gedas Greicius and Professor David Virshup, Director of the Programme in Cancer & Stem Cell Biology in Duke-NUS Medical School, studied the source and functional role of Wnts and RSPO3 [1]. RSPO3 is by far the most abundant R-spondin … Mechanism vital to keeping blood stem cells functional uncoveredScience Codex Why cells with identical genes perform unique jobs — ScienceDailyScience Daily |
EurekAlert (press release) |
It’s all about the (stem cell) neighborhood
EurekAlert (press release) A team headed by Gedas Greicius and Professor David Virshup, Director of the Programme in Cancer & Stem Cell Biology in Duke-NUS Medical School, studied the source and functional role of Wnts and RSPO3 [1]. RSPO3 is by far the most abundant R-spondin … Mechanism vital to keeping blood stem cells functional uncoveredScience Codex Why cells with identical genes perform unique jobs — ScienceDailyScience Daily |
EurekAlert (press release) |
It’s all about the (stem cell) neighborhood
EurekAlert (press release) Stems cells in our adult tissues live in very specific locations called stem cell niches. These niches provide a specialised, ideal neighbourhood for stem cells. The stem cells in the niche are undifferentiated, meaning they have not yet changed into a … |
STAT |
Incyte’s cancer drug fails trial, marking major blow for immunotherapy combination treatment
STAT he first real clinical test of the cancer immunotherapy combination thesis has come back negative. Incyte said Friday that its experimental drug epacadostat failed to improve the efficacy of Merck’s checkpoint inhibitor Keytruda when the two drugs were … Incyte tumbles after combo therapy with Merck fails studyCNBC Incyte slumps 19% after combo therapy fails late-stage testFinancial Times Incyte, Merck & Co. Halt Phase III Trial After Epacadostat/Keytruda Combination Fails in MelanomaGenetic Engineering & Biotechnology News Benzinga –Business Insider Australia all 146 news articles » |